GW&K Investment Management LLC raised its holdings in shares of Catalent Inc (NYSE:CTLT) by 13.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,010,273 shares of the company’s stock after buying an additional 235,371 shares during the period. Catalent comprises approximately 1.3% of GW&K Investment Management LLC’s investment portfolio, making the stock its 3rd biggest position. GW&K Investment Management LLC owned approximately 1.37% of Catalent worth $95,810,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the stock. Evolution Wealth Advisors LLC purchased a new stake in shares of Catalent in the 2nd quarter valued at approximately $32,000. Advisory Services Network LLC lifted its position in Catalent by 115.5% in the 2nd quarter. Advisory Services Network LLC now owns 737 shares of the company’s stock worth $39,000 after buying an additional 395 shares in the last quarter. Quest Capital Management Inc. ADV purchased a new stake in Catalent in the 3rd quarter worth approximately $53,000. Bamco Inc. NY purchased a new stake in Catalent in the 2nd quarter worth approximately $81,000. Finally, Point72 Hong Kong Ltd purchased a new stake in Catalent in the 2nd quarter worth approximately $165,000.
In other Catalent news, Director Gregory T. Lucier purchased 2,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were bought at an average price of $51.64 per share, for a total transaction of $103,280.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO John R. Chiminski sold 97,043 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $48.84, for a total transaction of $4,739,580.12. The disclosure for this sale can be found here. Corporate insiders own 1.30% of the company’s stock.
CTLT stock traded up $0.27 during midday trading on Friday, reaching $49.52. The company had a trading volume of 467,188 shares, compared to its average volume of 806,017. Catalent Inc has a 1 year low of $29.23 and a 1 year high of $58.38. The company has a current ratio of 2.06, a quick ratio of 1.70 and a debt-to-equity ratio of 2.74. The company has a market capitalization of $7.38 billion, a P/E ratio of 30.57, a PEG ratio of 2.47 and a beta of 1.69. The company has a 50 day moving average of $49.09 and a two-hundred day moving average of $50.57.
Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.26 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.07. Catalent had a net margin of 5.77% and a return on equity of 16.87%. The company had revenue of $664.70 million for the quarter, compared to analyst estimates of $634.87 million. During the same quarter in the prior year, the business posted $0.28 EPS. Catalent’s quarterly revenue was up 20.5% on a year-over-year basis. On average, sell-side analysts anticipate that Catalent Inc will post 1.81 earnings per share for the current year.
A number of equities research analysts have issued reports on CTLT shares. ValuEngine downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Zacks Investment Research downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Stephens started coverage on shares of Catalent in a research report on Thursday, October 17th. They issued an “overweight” rating and a $56.00 target price for the company. Robert W. Baird increased their target price on shares of Catalent from $50.00 to $60.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. Finally, Morgan Stanley increased their target price on shares of Catalent from $50.00 to $61.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 28th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $56.25.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: Dollar Cost Averaging
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.